AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1524140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate with high titer of anti-S. flexneri 2a LPS, administered three times a day for seven days.
Number of subjects: 0
Study 1524140 — intervention group
Group type: COMPARATOR
Intervention: Control preparation with sodium bicarbonate, administered three times a day for seven days.
Number of subjects: 0
Study 1524140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate with high titer of anti-S. flexneri 2a LPS.
Number of subjects: 0
Study 6470361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 15
Study 6470361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 15
Study 30675745 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaminal® Forte
Number of subjects: 89
Study 30675745 — intervention group
Group type: COMPARATOR
Intervention: Flamazine®
Number of subjects: 89
Study 30302881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dcau group (1 mL/kg of caudal 0.25% levobupivacaine plus 1 μg/kg dexmedetomidine and IV 20 mL saline)
Number of subjects: 90
Study 30302881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Div group (1 mL/kg of caudal 0.25% levobupivacaine and IV 1 μg/kg dexmedetomidine in 20 mL saline)
Number of subjects: 90
Study 30302881 — intervention group
Group type: COMPARATOR
Intervention: L group (1 mL/kg of caudal 0.25% levobupivacaine and IV 20 mL saline)
Number of subjects: 90
Study 30302881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dcau and L-Div groups
Number of subjects: 90
Study 30302881 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 26883420 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage revision THR
Number of subjects: 148
Study 26883420 — intervention group
Group type: COMPARATOR
Intervention: Two-stage revision THR
Number of subjects: 148
Study 25032872 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent conjugated vaccine
Number of subjects: 0
Study 25032872 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-polysaccharide vaccine
Number of subjects: 0
Study 25032872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (13-valent conjugated and 23-polysaccharide)
Number of subjects: 0
Study 22864456 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic aortic and pelvic lymphadenectomy (SAPL)
Number of subjects: 308
Study 22864456 — intervention group
Group type: COMPARATOR
Intervention: Resection of bulky nodes only (Control)
Number of subjects: 308
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 1 mg
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg (28 days)
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg (28 days)
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg (28 days)
Number of subjects: 2
Study 20160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound linagliptin
Number of subjects: 2
Study 17379591 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (once or twice daily)
Number of subjects: 45
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Antibiotic Therapy (SAT) combined with amikacin
Number of subjects: 152
Study 16583990 — intervention group
Group type: COMPARATOR
Intervention: Other Antibiotic Therapy (OAT) combined with amikacin
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin used in high once daily dose (HODD) with SAT or OAT
Number of subjects: 152
Study 16583990 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin HODD with TDM
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin HODD without TDM
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct costs of treatment with SAT
Number of subjects: 152
Study 16583990 — intervention group
Group type: COMPARATOR
Intervention: Direct costs of treatment with OAT
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization costs per patient
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost reduction by omitting TDM in patients without risk factors
Number of subjects: 152
Study 16583990 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cost reduction by introducing safe and cheap standard treatment
Number of subjects: 152
Study 12131102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 12131102 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 10819337 — intervention group
Group type: COMPARATOR
Intervention: DTaP + Hib + OPV
Number of subjects: 567
Study 10819337 — intervention group
Group type: COMPARATOR
Intervention: DTaP/Hib + OPV
Number of subjects: 567
Study 10819337 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP/Hib + IPV
Number of subjects: 567
Study 8829420 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block (T3-S5) prior to induction of anesthesia and surgery (Group A)
Number of subjects: 38
Study 8829420 — intervention group
Group type: COMPARATOR
Intervention: Spinal block performed after surgery prior to extubation of the trachea (Group B)
Number of subjects: 38
Study 1535638 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training (AT)
Number of subjects: 34
Study 1535638 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (WL) condition
Number of subjects: 34
Study 1535638 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play performance
Number of subjects: 34
Study 1535638 — intervention group
Group type: COMPARATOR
Intervention: Social and recreational activities
Number of subjects: 34
Study 2981789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 2981789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30343187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interactive/motivational computerized intervention
Number of subjects: 58
Study 30343187 — intervention group
Group type: COMPARATOR
Intervention: Static/educational computerized intervention
Number of subjects: 58
Study 28746738 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme focusing on developing emotional knowledge skills around daily health habits (eating, hygiene, sleep, and physical exercise) using game-based dynamics and an emotional diary.
Number of subjects: 30
Study 28746738 — intervention group
Group type: COMPARATOR
Intervention: Usual school routine (Control group).
Number of subjects: 30
Study 28746738 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme (experimental group).
Number of subjects: 30
Study 27521377 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer Supporter Programme (CSP)
Number of subjects: 291
Study 27521377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (RYCT)
Number of subjects: 291
Study 27521377 — intervention group
Group type: COMPARATOR
Intervention: CSP and RYCT combined
Number of subjects: 291
Study 27521377 — intervention group
Group type: COMPARATOR
Intervention: Usual care (TAU)
Number of subjects: 291
Study 27521377 — intervention group
Group type: COMPARATOR
Intervention: CSP
Number of subjects: 291
Study 24910935 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire-assisted transpancreatic sphincterotomy (GATS)
Number of subjects: 149
Study 24910935 — intervention group
Group type: COMPARATOR
Intervention: Needle-knife sphincterotomy (NKS)
Number of subjects: 149
Study 24910935 — intervention group
Group type: COMPARATOR
Intervention: Both GATS and NKS
Number of subjects: 149
Study 21975687 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 72
Study 21975687 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 72
Study 20684665 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP heparin plaster
Number of subjects: 233
Study 20684665 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 233
Study 18671909 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injection plus ankle‐foot casting (n=6)
Number of subjects: 13
Study 18671909 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (BTA) alone (n=7)
Number of subjects: 13
Study 15741721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice
Number of subjects: 16
Study 15741721 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 16
Study 12567340 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral block with 20 mL 1% ropivacaine
Number of subjects: 80
Study 12567340 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of 20 mL 1% ropivacaine
Number of subjects: 80
Study 10080505 — intervention group
Group type: EXPERIMENTAL
Intervention: Human EEG reviewers
Number of subjects: 7
Study 10080505 — intervention group
Group type: COMPARATOR
Intervention: Gotman automatic spike-detection system
Number of subjects: 7
Study 10080505 — intervention group
Group type: COMPARATOR
Intervention: Wavelet detector
Number of subjects: 7
Study 10080505 — intervention group
Group type: COMPARATOR
Intervention: Two-stage system
Number of subjects: 7
Study 7769193 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms q.i.d. for 13 doses) during indomethacin treatment (50 mg p.o. t.i.d. for 10 doses)
Number of subjects: 7
Study 7769193 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg p.o. t.i.d. for 10 doses)
Number of subjects: 7
Study 7769193 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment only
Number of subjects: 7
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of salbutamol delivered by a micronebulizer LSA on admission (HO)
Number of subjects: 26
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of additional salbutamol nebulised at H1 if less than 20% increase in PEF
Number of subjects: 26
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline or salbutamol intravenously given in a randomised fashion for Group II
Number of subjects: 26
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of treatments at H8 for Group II in cases of failures
Number of subjects: 26
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 26
Study 2320783 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg's scale dyspnoea level greater than 5 and peak flow less than 150 l/min
Number of subjects: 26
Study 394754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral choline theophyllinate
Number of subjects: 14
Study 394754 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 14
Study 394754 — intervention group
Group type: COMPARATOR
Intervention: Reduction of the dose of beclomethasone from 400 microgram/day
Number of subjects: 14
Study 31127718 — intervention group
Group type: EXPERIMENTAL
Intervention: Online recruitment
Number of subjects: 780
Study 31127718 — intervention group
Group type: COMPARATOR
Intervention: General practice recruitment
Number of subjects: 780
Study 31127718 — intervention group
Group type: COMPARATOR
Intervention: Other sources recruitment
Number of subjects: 780
Study 28878436 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based health literacy intervention
Number of subjects: 41
Study 28878436 — intervention group
Group type: COMPARATOR
Intervention: Text message reminders (control)
Number of subjects: 41
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Pa-Z
Number of subjects: 15
Study 25622149 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 15
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Z-C
Number of subjects: 15
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Pa-Z-C
Number of subjects: 15
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Pa-C
Number of subjects: 15
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: Z alone
Number of subjects: 15
Study 25622149 — intervention group
Group type: EXPERIMENTAL
Intervention: C alone
Number of subjects: 15
Study 23256585 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gas reduction (Group 1)
Number of subjects: 200
Study 23256585 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 200
Study 21076311 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times a week for 8 weeks)
Number of subjects: 32
Study 21076311 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 32
Study 21076311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 19617879 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of pidolate Mg(2+) daily for 12 weeks
Number of subjects: 48
Study 19617879 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle recommendations only (Control)
Number of subjects: 48
Study 17076751 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years video-based 14-week group programme
Number of subjects: 76
Study 15570204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery
Number of subjects: 60
Study 15570204 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study 11697691 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with epinephrine (1:80,000)
Number of subjects: 100
Study 9388800 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP curriculum
Number of subjects: 242
Study 9388800 — intervention group
Group type: COMPARATOR
Intervention: GN curriculum
Number of subjects: 242
Study 9388800 — intervention group
Group type: COMPARATOR
Intervention: GN or SNAP curriculum
Number of subjects: 242
Study 7974570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 238
Study 7974570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 200 mg/day
Number of subjects: 238
Study 2741218 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP regimen (cyclophosphamide 200 mg/m2 i.v. days 1, 3 and 5, adriamycin 40 mg/m2 i.v. day 1, platinum 30 mg/m2 i.v. day 1, 3 and 5)
Number of subjects: 126
Study 2741218 — intervention group
Group type: COMPARATOR
Intervention: FAC regimen (5‐FU 500 mg/m2 days 1 and 8, adriamycin 50 mg/m2 day 1, cyclophosphamide 500 mg/m2 day 1)
Number of subjects: 126
Study 2741218 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CAP and FAC
Number of subjects: 126
Study 239971 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject control, graduated exposure, feedback
Number of subjects: 15
Study 239971 — intervention group
Group type: COMPARATOR
Intervention: Experimenter control, graduated exposure, feedback
Number of subjects: 15
Study 239971 — intervention group
Group type: COMPARATOR
Intervention: Experimenter control, nongraduated exposure, feedback
Number of subjects: 15
Study 239971 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study 31216826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (more than 50 Gy dose)
Number of subjects: 125
Study 31216826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (more than 5 weeks)
Number of subjects: 125
Study 31216826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (1-4 weeks)
Number of subjects: 125
Study 31216826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy
Number of subjects: 125
Study 28371298 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD enriched with virgin olive oil (TMD-VOO, N = 71)
Number of subjects: 210
Study 28371298 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD enriched with nuts (TMD-Nuts, N = 68)
Number of subjects: 210
Study 28371298 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (N = 71)
Number of subjects: 210
Study 25988769 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (34 mg/day of zinc)
Number of subjects: 70
Study 25988769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 70
Study 22943577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 30
Study 22943577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21431424 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in forest environments
Number of subjects: 16
Study 21431424 — intervention group
Group type: COMPARATOR
Intervention: Walking in urban area (control)
Number of subjects: 16
Study 21431424 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 16
Study 19638966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone citrate 10 mg t.i.d. for 4 weeks
Number of subjects: 144
Study 19638966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone citrate
Number of subjects: 144
Study 19638966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 17598639 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 82
Study 17598639 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 82
Study 17598639 — intervention group
Group type: EXPERIMENTAL
Intervention: eprosartan (600 mg)
Number of subjects: 82
Study 17598639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study 15569038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 961
Study 15569038 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 961
Study 11568071 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular graft (EVG) treatment
Number of subjects: 45
Study 11568071 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical repair (OSR) treatment
Number of subjects: 45
Study 11568071 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 45
Study 9990214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 10 mg
Number of subjects: 32
Study 9990214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 5 mg
Number of subjects: 32
Study 9990214 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 8091765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 86
Study 8091765 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 86
Study 3378660 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide-amiloride
Number of subjects: 47
Study 3378660 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide-potassium chloride
Number of subjects: 47
Study 29406853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (60 mg and 90 mg)
Number of subjects: 12558
Study 29406853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12558
Study 28786805 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling sessions (4 sessions at months 0, 2, 4, and 6)
Number of subjects: 298
Study 25620436 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 198
Study 25620436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 5 mg once daily
Number of subjects: 198
Study 25620436 — intervention group
Group type: COMPARATOR
Intervention: Both enoxaparin and fondaparinux
Number of subjects: 198
Study 23725919 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 2 g once daily
Number of subjects: 610
Study 23725919 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 4 g twice daily
Number of subjects: 610
Study 23725919 — intervention group
Group type: COMPARATOR
Intervention: EPA-E 1.8 g/day
Number of subjects: 610
Study 19955822 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 19955822 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 18245013 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0
Study 18245013 — intervention group
Group type: COMPARATOR
Intervention: Immediate treatment for screen‐diagnosed lung cancer
Number of subjects: 0
Study 18245013 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment for screen‐diagnosed lung cancer
Number of subjects: 0
Study 16787894 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsivity education/prelinguistic milieu teaching (RE/PMT)
Number of subjects: 51
Study 16787894 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 51
Study 12934464 — intervention group
Group type: EXPERIMENTAL
Intervention: Current methods of OP prevention and treatment
Number of subjects: 0
Study 10868643 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (250 mg i.v. methylprednisolone at 1 and 6 hr)
Number of subjects: 101
Study 10868643 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (500 mg i.v. methylprednisolone at 1 hr before initial OKT3)
Number of subjects: 101
Study 10868643 — intervention group
Group type: COMPARATOR
Intervention: Group III (Atgam 15 mg/kg on day 0, OKT3 on day 1)
Number of subjects: 101
Study 10868643 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 101
Study 10868643 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 101
Study 10868643 — intervention group
Group type: COMPARATOR
Intervention: Group III
Number of subjects: 101
Study 9195083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg once daily for 14 days)
Number of subjects: 167